Skip to main content
. Author manuscript; available in PMC: 2019 Dec 6.
Published in final edited form as: Drug Discov Today. 2017 Nov 15;23(5):1007–1015. doi: 10.1016/j.drudis.2017.11.010

FIGURE 4.

FIGURE 4

Illustration of challenges in personalized nanomedicine developed to target central nervous system (CNS) diseases (a), and schematic presentation of public–private partnership involving key stakeholders and US Food and Drug Administration (FDA) to promote and protect public health (b). Reproduced from Ref. [64]. Abbreviations: BBB, blood–brain barrier; NF, nanoformulation.